Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615.

INTRODUCTION

CD38 and BCMA are proteins expressed at high levels in multiple myeloma cells, so they are targets for the development of mono- or multispecific antibodies.

AREAS COVERED: Patent US20240132615 describes anti-CD3/BCMA/CD38 trispecific antibodies and a method of treating relapsed/refractory multiple myeloma pharmaceutically. In vitro and preclinical results show that anti-CD3/BCMA/CD38 trispecific antibodies have stronger binding affinity and killing potency compared to daratumumab, isatuximab, and teclistamab antibodies.

EXPERT OPINION: The trispecific structure and a silenced Fc are pharmaceutical advantages of the anti-CD3/BCMA/CD38 antibody for the treatment of relapsed or refractory multiple myeloma.